US EditionPublished • loading... • Updated
DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Epcoritamab improved progression-free survival by 26% in a global Phase 3 trial of 483 patients with relapsed/refractory diffuse large B-cell lymphoma ineligible for transplant.
- AbbVie and Genmab announced topline EPCORE DLBCL-1 results showing a PFS improvement and plan to engage regulators, as of Jan. 16, 2026.
- The EPCORE DLBCL-1 Phase 3 trial enrolled 483 adults with relapsed/refractory DLBCL, most with two or more prior lines and ineligible for HDT‑ASCT.
- Epcoritamab is designed to bind CD3 on T cells and CD20+ B cells and is administered subcutaneously, showing improvements in complete response rates, duration of response and time to next treatment.
- Despite PFS improvement, the study lacked a statistically significant OS result and sponsors are assessing contributing factors, while AbbVie and Genmab remain committed to ongoing clinical development programs.
- With approvals in more than 65 countries, AbbVie and Genmab will pursue additional international filings that could expand options for patients ineligible for HDT‑ASCT.
Insights by Ground AI
18 Articles
18 Articles
abc12/WJRT+12 Reposted by 12 other sources
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Based on the topline results from the EPCORE® DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss next steps
·Flint, United States
Read Full Article
Coverage Details
Total News Sources18
Leaning Left1Leaning Right1Center8Last UpdatedBias Distribution80% Center
Bias Distribution
- 80% of the sources are Center
80% Center
C 80%
Factuality
To view factuality data please Upgrade to Premium
